# The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

> **NCT07381634** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 134 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- IrAE

## Interventions

- **DRUG:** ondansetron

## Key facts

- **NCT ID:** NCT07381634
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-06-20
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381634, "The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07381634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*